VIPIT

Subject: Science & tech

Context: The curious case of VIPIT: Studies needed to identify susceptibility markers, diagnostic tests, treatments.

Concept:

The United Kingdom, European Union, and Scandinavian countries have reported that the AstraZeneca COVID-19 vaccine appears to be associated with rare cases of serious blood clots, including blood clots in the brain.
These blood clots have two important features: they occur 4 to 20 days after vaccination, and they are associated with low platelets (tiny blood cells that help form blood clots to stop bleeding).
Doctors are calling this “vaccine-induced prothrombotic immune thrombocytopenia” (VIPIT).
VIPIT seems to be rare, occurring in anywhere from 1 in every 125,000 to 1 in 1 million people.
There have been no confirmed cases of VIPIT with any other COVID-19 vaccine.